Filing Flows

Filing Flows › Companies › Viemed Healthcare › Cash flow

Viemed Healthcare cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow$2.9M in Q3 2026 · $21.4M over twelve months

Operating cash flow$11.5M
Capital spending−$8.6M
Free cash flow+$2.9M
Cash / net income2.4×
Cash conversion cycle23 days

Analysis

In Q3 2026, Viemed Healthcare generated $11.5M of operating cash flow and spent $8.6M on capital projects, leaving free cash flow of $2.9M. That is $7.9M less than in Q3 2025 ($10.7M).

Over the twelve months to Sep 30, 2026, operating cash flow was $53.9M; the largest uses were capital spending ($32.5M), other financing ($9.7M), net borrowing (+) / repaid (−) ($8.0M); besides operations, cash came from asset & business sales ($4.7M), shares issued ($1.1M); the cash balance fell by $1.4M.

Operating cash flow was $11.5M against net income of $4.7M — 2.4× profit, cash ran ahead of reported earnings. The largest differences: depreciation & amortization +$7.7M, prepaid and other assets −$4.3M, receivables −$2.7M.

Its cash conversion cycle was 23 days (receivables 38 + inventory 13 − payables 29).

Free cash flow

Viemed Healthcare: free cash flow by quarterViemed Healthcare: free cash flow by quarter$3.2MQ4 2024−$12.6MQ1 2025$4.1MQ2 2025$10.7MQ3 2025$9.7MQ4 2025$1.4MQ1 2026$7.4MQ2 2026$2.9MQ3 2026
Operating cash flow less capital spending.
Viemed Healthcare: operating cash flow against capital spendingViemed Healthcare: operating cash flow against capital spendingOperating cash flowCapital spending$15.0M$11.8MQ4 2024$2.9M$15.5MQ1 2025$12.3M$8.1MQ2 2025$18.4M$7.6MQ3 2025$18.4M$8.7MQ4 2025$8.1M$6.7MQ1 2026$15.9M$8.5MQ2 2026$11.5M$8.6MQ3 2026
Latest (Q3 2026): Operating cash flow $11.5M, Capital spending $8.6M.

Capital allocation, year by year

Viemed Healthcare: where the cash came from (up) and went (down), by fiscal yearViemed Healthcare: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedAsset salesCapital spendingAcquisitionsBuybacksFY2021: Operating cash flow $22.5MFY2021: Net borrowing −$1.7MFY2021: Shares issued $112KFY2021: Asset sales $596KFY2021: Capital spending −$19.7M$23.2MFY2021FY2022: Operating cash flow $27.7MFY2022: Net borrowing −$1.4MFY2022: Shares issued $283KFY2022: Asset sales $1.1MFY2022: Capital spending −$22.9MFY2022: Buybacks −$9.6M$29.1MFY2022FY2023: Operating cash flow $45.2MFY2023: Net borrowing $995KFY2023: Shares issued $1.3MFY2023: Asset sales $2.6MFY2023: Capital spending −$26.1MFY2023: Acquisitions −$28.6M$50.1MFY2023FY2024: Operating cash flow $39.1MFY2024: Net borrowing −$5.0MFY2024: Shares issued $1.0MFY2024: Asset sales $10.3MFY2024: Capital spending −$37.8MFY2024: Acquisitions −$3.0M$50.4MFY2024FY2025: Operating cash flow $51.9MFY2025: Net borrowing −$50KFY2025: Shares issued $1.4MFY2025: Asset sales $16.2MFY2025: Capital spending −$40.0MFY2025: Acquisitions −$26.3MFY2025: Buybacks −$13.2M$69.5MFY2025
Over these 5 years operating cash flow totalled $186M; the largest uses were capital spending ($146M) and acquisitions ($57.9M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$9.7M
Debt$5.0M
Net cash$4.7M
Due within a year$511K

Viemed Healthcare funds itself: free cash flow was $21.4M over the last twelve months, and $9.7M of cash and investments stands against $5.0M of debt ($511K due within a year, 18.9× covered by cash).

Where the cash came from and went

Viemed Healthcare: sources (+) and uses (−) of cash, Q3 2026Viemed Healthcare: sources (+) and uses (−) of cash, Q3 2026Operating cash flow$11.5MOther financing−$9.3MCapital spending−$8.6MNet borrowing (+) / repaid (−)$5.4MAsset & business sales$1.2MCash drawn (+) / kept (−)$1.0MBuybacks−$977KPartners−$136KTaxes on employees’ shares−$44KShares issued$14K
Viemed Healthcare: sources (+) and uses (−) of cash, TTM to Q3 2026Viemed Healthcare: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow$53.9MCapital spending−$32.5MOther financing−$9.7MNet borrowing (+) / repaid (−)−$8.0MBuybacks−$7.7MAsset & business sales$4.7MTaxes on employees’ shares−$2.1MCash drawn (+) / kept (−)$1.4MShares issued$1.1MOther investing−$552KPartners−$531K

From profit to cash

Viemed Healthcare: net income to operating cash flow, Q3 2026Viemed Healthcare: net income to operating cash flow, Q3 2026Net income$4.7MDepreciation & amortization$7.7MStock-based pay$2.5MGains on disposals$412KReceivables−$2.7MInventory$716KPayables$600KAccrued liabilities$1.7MDeferred revenue$12KPrepaid and other assets−$4.3MIncome taxes payable$95KOperating cash flow$11.5M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 202638132923
Q2 202637142724
Q1 202634142226
Q4 202532152324
Q3 202535142523
Q2 202538152826
Q1 202539152332
Q4 202439162134

Every quarter

QuarterOperating cash flowCapital spendingAcquisitionsBuybacksNet borrowing (+) / repaid (−)Shares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026$11.5M−$8.6M—−$977K$5.4M$14K$1.0M$2.9M
Q2 2026$15.9M−$8.5M—−$5.3M−$2.2M$531K−$918K$7.4M
Q1 2026$8.1M−$6.7M—−$1.4M−$3.2M$526K$3.7M$1.4M
Q4 2025$18.4M−$8.7M——−$8.0M—−$2.4M$9.7M
Q3 2025$18.4M−$7.6M−$26.3M−$11.6M$8.2M$71K$8.9M$10.7M
Q2 2025$12.3M−$8.1M—−$1.7M−$124K$1.4M−$9.9M$4.1M
Q1 2025$2.9M−$15.5M——−$131K$11K$7.4M−$12.6M
Q4 2024$15.0M−$11.8M——−$19K$601K−$6.2M$3.2M

Viemed Healthcare: income statement and cash flow

Viemed Healthcare, Q3 2026: revenue $80.7M (+12% year over year), operating margin 8.6%. The chart follows the revenue to costs, profit and cash.

Viemed Healthcare: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.